Insights

Strategic Collaboration Merus actively pursues global partnerships and licensing opportunities, notably with Halozyme for subcutaneous formulations and Partner Therapeutics for US commercialization of Zeno, indicating strong potential for co-development and commercial licensing conversations.

Late-stage Potential Genmab’s proposed $8B acquisition of Merus to obtain rights to petosemtamab signals high-value assets and imminent late-stage opportunities, suggesting readiness for high-stakes licensing deals, strategic partnerships, or co-commercial arrangements.

Diagnostic Synergy Existing collaborations to develop RNA-based companion diagnostics with Foundation Medicine enhance Zeno's translational potential, presenting an avenue to propose integrated diagnostic-genetic testing solutions with pivotal trial support and market access advantages.

Industry Footprint Merus operates across the US, Europe, and global collaborators with a mid-sized team, indicating a nimble organization suitable for targeted BD outreach, rightsizing deal structures, and multi-region commercialization planning.

Financial Leverage With substantial funding and a multi-year revenue stream alongside a broad partner ecosystem, Merus is positioned to evaluate milestone-driven deals, upfront payments, and royalty-based models that align with its growth trajectory and pipeline milestones.

Similar companies to Merus N.V.

Merus N.V. Tech Stack

Merus N.V. uses 8 technology products and services including Power BI, SAS, Drupal, and more. Explore Merus N.V.'s tech stack below.

Media & News

Merus N.V.'s Email Address Formats

Merus N.V. uses at least 3 email formats:
Merus N.V. Email FormatsExamplePercentage
F.Last@merus.nlJ.Doe@merus.nl
74%
First.Last@merus.nlJohn.Doe@merus.nl
13%
First_Last@merus.nlJohn_Doe@merus.nl
13%

Frequently Asked Questions

What is Merus N.V.'s phone number?

Minus sign iconPlus sign icon
You can contact Merus N.V.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Merus N.V.'s stock symbol?

Minus sign iconPlus sign icon
Merus N.V. is a publicly traded company; the company's stock symbol is MRUS.

What is Merus N.V.'s official website and social media links?

Minus sign iconPlus sign icon
Merus N.V.'s official website is merus.nl and has social profiles on LinkedIn and Crunchbase.

How much revenue does Merus N.V. generate?

Minus sign iconPlus sign icon
As of October 2026, Merus N.V.'s annual revenue is estimated to be $25M - $50M.

What is Merus N.V.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
Merus N.V.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Merus N.V. have currently?

Minus sign iconPlus sign icon
As of October 2026, Merus N.V. has approximately 195 employees across 3 continents, including Europe, North America and South America. Key team members include Chief Executive Officer: M. C., Cto: J. D. K. and Chief Scientific Officer: C. G. Explore Merus N.V.'s employee directory with LeadIQ.

What industry does Merus N.V. belong to?

Minus sign iconPlus sign icon
Merus N.V. operates in the Biotechnology Research industry.

What technology does Merus N.V. use?

Minus sign iconPlus sign icon
Merus N.V.'s tech stack includes Power BI, SAS, Drupal, Microsoft SharePoint, Hyperion, Google Cloud, Smartsheet and New Relic.

What is Merus N.V.'s email format?

Minus sign iconPlus sign icon
Merus N.V.'s email format typically follows the pattern of F.Last@merus.nl. Find more Merus N.V. email formats with LeadIQ.

How much funding has Merus N.V. raised to date?

Minus sign iconPlus sign icon
As of October 2026, Merus N.V. has raised $1.4B in funding. The last funding round occurred on Jun 03, 2025 for $300M.
Merus N.V. logo

Merus N.V.

Biotechnology ResearchUtrecht, Netherlands51-200 Employees

Merus N.V. is a biotechnology research company focused on developing cancer therapeutics, with its most advanced programs built around Biclonics, a bispecific antibody approach designed to engage the immune system while directly inhibiting tumor growth and survival pathways. The company aims to provide multi-pronged anti-cancer therapies and has several candidates in clinical trials. It is headquartered in Utrecht, Netherlands, with offices in the United States and collaborations around the world, and it has been listed on NASDAQ since 2016. 

Within oncology, Merus collaborates with other organizations to advance its therapies and diagnostic strategies. A notable recent development is an exclusive license agreement announced in December 2024 with Partner Therapeutics for the commercialization of zenocutuzumab (Zeno) for NRG1+ cancers.

Section iconCompany Overview

Phone number
Website
merus.nl
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
MRUS
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconFunding & Financials

  • $1.4B

    Merus N.V. has raised a total of $1.4B of funding over 12 rounds. Their latest funding round was raised on Jun 03, 2025 in the amount of $300M as a Post IPO Equity.

  • $25M - $50M

    Merus N.V.'s revenue is estimated to be in the range of $25M - $50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.